These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 24136223)
21. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654 [TBL] [Abstract][Full Text] [Related]
22. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK. Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233 [TBL] [Abstract][Full Text] [Related]
23. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study. Casalvieri KA; Matheson CJ; Backos DS; Reigan P Bioorg Med Chem; 2020 Mar; 28(5):115303. PubMed ID: 31982240 [TBL] [Abstract][Full Text] [Related]
24. The Vascular Endothelial Growth Factor-A phosphorylates Murine Double Minute-2 on its Serine 166 via the Extracellular Signal-Regulated Kinase 1/2 and p90 Ribosomal S6 Kinase in primary human endothelial cells. Aiken J; Birot O Biochem Biophys Res Commun; 2016 Sep; 478(4):1548-54. PubMed ID: 27591897 [TBL] [Abstract][Full Text] [Related]
25. Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism. Smadja-Lamère N; Shum M; Déléris P; Roux PP; Abe J; Marette A J Biol Chem; 2013 Oct; 288(43):31165-76. PubMed ID: 24036112 [TBL] [Abstract][Full Text] [Related]
26. Synthesis of a potent and selective inhibitor of p90 Rsk. Maloney DJ; Hecht SM Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148 [TBL] [Abstract][Full Text] [Related]
27. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694 [TBL] [Abstract][Full Text] [Related]
28. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917 [TBL] [Abstract][Full Text] [Related]
29. Protective mechanism of artemisinin on rat bone marrow-derived mesenchymal stem cells against apoptosis induced by hydrogen peroxide via activation of c-Raf-Erk1/2-p90 Fang J; Zhao X; Li S; Xing X; Wang H; Lazarovici P; Zheng W Stem Cell Res Ther; 2019 Oct; 10(1):312. PubMed ID: 31655619 [TBL] [Abstract][Full Text] [Related]
39. p90 ribosomal S6 kinases play a significant role in early gene regulation in the cardiomyocyte response to G(q)-protein-coupled receptor stimuli, endothelin-1 and α(1)-adrenergic receptor agonists. Amirak E; Fuller SJ; Sugden PH; Clerk A Biochem J; 2013 Mar; 450(2):351-63. PubMed ID: 23215897 [TBL] [Abstract][Full Text] [Related]
40. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]